Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2424729 | 0.94 | HRH3 (0.69) | HRH3NPC1RAB9ASMN1; SMN2MAPT | |
| Trifluoroacetic Acid SCHEMBL2426535 | 0.88 | HRH3 (0.65) | HRH3NPC1RAB9ASMN1; SMN2MAPT | |
| Trifluoroacetic Acid SCHEMBL2421792 | 0.88 | HRH3 (0.66) | HRH3KCNH2POLB | |
| Trifluoroacetic Acid SCHEMBL1729651 | 0.84 | HRH3 (0.89) | HRH3NPC1RAB9ASMN1; SMN2MAPT | |
| Trifluoroacetic Acid SCHEMBL2423239 | 0.84 | HRH3 (0.68) | HRH3NPC1RAB9ASMN1; SMN2MAPT | |
| Trifluoroacetic Acid SCHEMBL2422122 | 0.82 | HRH3 (0.61) | HRH3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL223740 | 0.82 | HRH3 (0.65) | HRH3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2422328 | 0.82 | HRH3 (0.73) | HRH3 | |
| Trifluoroacetic Acid SCHEMBL2423337 | 0.82 | HRH3 (0.65) | HRH3NPC1RAB9ASMN1; SMN2MAPT | |
| Trifluoroacetic Acid SCHEMBL1728317 | 0.82 | HRH3 (0.86) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212282-B1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-20100173897-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173897-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | HRH3 1/4885NPC1 1047/4885RAB9A 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.